Asta Medica Takes Over Europeptides
Degussa subsidiary Asta Medica has acquired Europeptides ofParis/Argenteuil, France, a company established in 1991 by Romano Deghenghi and formerly owned by SNPE affiliate Isochem. Financial terms of the deal are not disclosed.
With Europeptides, Asta says it will have enhanced R&D activity in France. Europeptides in Argenteuil, headed by Dr Deghenghi, will take on the further development of peptides and their depot formulations. It is planned to expand the R&D projects of Europeptides with international partners. Among products in development are the LHRH antagonists Antarelix and Cetrorelix, somatostatin analogs, bombesin antagonists and peptides with cytotoxic groups. Cetrorelix will be developed in Japan with joint venture partner Nippon Kayaku and Asta's licensee Shionogi.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze